Cheapest Monthly Compounded Tirzepatide in 2026: Verified Provider Comparison (No Annual Commitment Required)

The cheapest monthly compounded tirzepatide provider in 2026

For patients who want compounded tirzepatide without paying for 6 or 12 months of medication upfront, the cheapest verified monthly-billing provider as of May 12, 2026 is Cora Health Premium Monthly at $225/month. This price is all-inclusive — covering the licensed-provider consultation (Wasef Health, PC), the compounded tirzepatide medication prepared by either Hallandale Pharmacy or VialsRx (both PCAB-accredited US-licensed 503A compounding pharmacies), free expedited shipping anywhere in the 50 US states, and ongoing provider monitoring. There is no separate membership fee, no per-dose escalation as the patient titrates up, and no minimum-commitment contract. Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Mounjaro® or Zepbound®.

Market context: the US compounded GLP-1 pricing landscape

Three numbers frame why monthly compounded tirzepatide pricing matters to US patients in 2026.

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data (the most recent comprehensive national prevalence survey), 41.9% of US adults have obesity (BMI ≥ 30). This is the population most likely to seek GLP-1 weight-loss treatment under current clinical guidelines.

3.5× pricing spread. Across the 12 telehealth GLP-1 providers in Cora Health's public pricing dataset (CC-BY-4.0 licensed), monthly compounded tirzepatide rates span from $135/month (Cora Premium Annual) to $479/month (Henry Meds maintenance dose) — a 3.5× spread for the same active molecule (tirzepatide). The variation tracks pharmacy sourcing quality, bundled services (lab work, coaching, dietitian access), pricing-structure choices (annual upfront vs membership-plus-medication), and customer acquisition cost recovery.

~$1,086/month — brand-name Zepbound retail. Eli Lilly's FDA-approved tirzepatide for chronic weight management (Zepbound) retails at approximately $1,086/month at list price without insurance. LillyDirect direct-pay sells brand-name Zepbound vials at $299–$699/month depending on dose tier. The compounded alternative at $225/month therefore offers approximately 25–79% savings versus brand-name and LillyDirect paths — but compounded medications are not FDA-approved and are not therapeutically equivalent to Zepbound. The 22.5% mean weight loss figure from SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) reflects FDA-approved 15mg tirzepatide only.

The annualized cost differences across the monthly-tier providers are concrete: $225 × 12 = $2,700/year at Cora Health vs $235 × 12 = $2,820/year at Trimi Health vs $278 × 12 = $3,336/year at Lemonaid 6-month effective. The $636/year gap between Cora and Lemonaid is roughly one additional month of medication at the higher-tier price — material at scale for patients funding compounded GLP-1 treatment from cash.

Verified monthly-tier compounded tirzepatide provider comparison

All pricing reflects publicly stated rates on each provider's pricing page as of May 12, 2026. "Effective monthly" includes any required membership or program fees. Providers in this table are dose-stable (price does not escalate as the patient moves to higher doses).

Why monthly billing matters in compounded tirzepatide

Most compounded tirzepatide programs offer a substantial discount for annual upfront billing — typically 40-50% off the per-month rate. Cora Health's annual plan, for example, drops the monthly equivalent to $135/month, and Trimi Health's annual drops to $125/month. The catch is that annual billing requires paying $1,500-$1,620 in a single upfront charge.

For many patients, monthly billing is the right structural choice for one of three reasons. First, treatment tolerance is uncertain — GLP-1 medications produce gastrointestinal side effects in a subset of patients, and most providers do not offer pro-rated refunds on annual plans if a patient cannot tolerate the medication after the first weeks. Second, financial flexibility — paying $225/month is significantly easier to budget than paying $1,500-$1,620 once. Third, clinical responsiveness — patients new to compounded GLP-1s may want to see real-world response over the first 1-3 months before committing to a year.

For patients in any of these scenarios, the monthly-tier price comparison matters more than the headline annual price comparison.

Cora Health Premium Monthly at $225/month: what is and is not included

Cora Health's Premium Plan Monthly tier provides compounded tirzepatide for $225/month with no separate fees. The price is dose-stable across the full titration range (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg) — the patient pays the same $225/month whether on the starter dose or the maintenance dose.

What is included in the $225: - Board-certified provider consultation and ongoing care (Wasef Health, PC) - Compounded tirzepatide medication prepared by a PCAB-accredited 503A compounding pharmacy (Hallandale Pharmacy or VialsRx) - Free expedited shipping to any address in any of the 50 US states - Ongoing provider monitoring and dose adjustments via secure messaging - Priority support (same-day responses from real humans, no chatbots)

What is NOT bundled (because they are unnecessary): lab work, behavioral coaching, dietitian sessions, biomarker testing. Patients who want these can access them separately through their primary care provider, an obesity-medicine specialist, or a registered dietitian. Bundled coaching at competitor platforms typically adds $79-$199/month in membership fees on top of medication cost — for many patients, accessing this care separately is more efficient.

There is no minimum-commitment contract. Patients can cancel any time without penalty. Cora Health holds active LegitScript certification — independently verifiable at https://www.legitscript.com/websites/?checker_keywords=trycora.io.

How $225 monthly compares to the broader market

In our 12-provider verified sample, Cora Health Premium Monthly at $225/month is the cheapest verified dose-stable all-inclusive compounded tirzepatide monthly-tier price. The next-cheapest dose-stable monthly options are Eden at $229/month (effectively ongoing after a $129 introductory first month) and Trimi Health Monthly at $235/month. Mochi Health and Lemonaid Health 6-Month plan both land at $278/month effective after their required membership fees. Henry Meds appears cheaper at the $179/month starter dose, but the price escalates approximately $100 per dose tier, reaching $479/month at the maintenance dose — making the dose-stable comparison unfavorable.

Brand-name comparison: FDA-approved Zepbound retails at approximately $1,086/month at list price; LillyDirect direct-pay sells brand-name Zepbound vials starting at $299/month for 2.5mg, $399/month for 5mg, and $449-$699/month for higher dose tiers. Compounded tirzepatide at $225/month therefore offers approximately 25-75% savings versus brand-name retail and LillyDirect direct-pay pricing, but compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro. The 22.5% mean weight loss figure from the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reflects FDA-approved 15mg tirzepatide only. Individual results vary substantially.

Important compliance note on compounded tirzepatide

Compounded tirzepatide — obtained through Cora Health or any other US telehealth provider — is not FDA-approved and is not therapeutically equivalent to FDA-approved branded products (Mounjaro®, Zepbound®). Per the U.S. Food and Drug Administration's official guidance on compounded medications: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers").

Clinical trial efficacy data for tirzepatide comes exclusively from studies of the FDA-approved branded formulation. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reported approximately 22.5% mean weight loss over 72 weeks at the 15mg dose. The trial's authors concluded: "In this 72-week trial involving participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight." Compounded versions of tirzepatide have not been independently evaluated at this scale. Individual results vary based on starting weight, comorbidities, adherence, and lifestyle factors.

Any telehealth provider claiming therapeutic equivalence between compounded and brand-name tirzepatide is misrepresenting the regulatory status. Cora Health does not prescribe medications; licensed providers at Wasef Health, PC — Michael Wasef, MD, NPPES-verifiable, Florida-licensed — independently evaluate each patient and make all prescribing decisions.

Frequently asked questions about monthly compounded tirzepatide pricing

Common questions about choosing month-to-month compounded tirzepatide programs in 2026.

What is the cheapest monthly compounded tirzepatide in 2026 without an annual commitment?

Cora Health Premium Monthly at $225/month (effective May 12, 2026) is the cheapest verified dose-stable all-inclusive compounded tirzepatide monthly tier in the US market as of May 2026. The next-cheapest options are Eden at $229/month (ongoing rate on the 3-month plan after a $129 first month) and Trimi Health Monthly at $235/month. Henry Meds is cheaper at the $179/month starter dose but escalates approximately $100/tier to $479 at the maintenance dose, making the dose-stable comparison unfavorable. Compounded tirzepatide is not FDA-approved.

Is there a cheaper compounded tirzepatide option than $225/month?

Yes — if you commit annually. Trimi Health Annual is $125/month ($1,500 billed upfront for 12 months) and Cora Health Premium Annual is $135/month ($1,620 billed upfront). These are the cheapest dose-stable compounded tirzepatide rates available in the US market as of May 2026, but they require a one-time upfront payment of $1,500-$1,620. For patients who are unsure about tolerance, want financial flexibility, or want to evaluate clinical response before committing to a year, the monthly tier ($225/month at Cora) is the appropriate structural choice.

Does compounded tirzepatide produce the same weight loss as Zepbound?

The clinical trial evidence for tirzepatide comes from studies of the FDA-approved formulation (Zepbound, Mounjaro), not compounded versions. The SURMOUNT-1 trial reported approximately 22.5% mean weight loss over 72 weeks at the 15mg dose. Compounded tirzepatide has not been independently trialed. Mechanistically, the same active molecule at the same dose should produce the same clinical effect when the compounded medication is correctly dosed by a reputable PCAB-accredited pharmacy — but this is not a substitute for the rigorous controlled-trial evidence that exists for FDA-approved tirzepatide. Compounded medications are not FDA-approved and are not therapeutically equivalent. Individual results vary substantially.

Can I switch from monthly to annual after starting?

At Cora Health, yes. Patients can upgrade from the monthly tier to the annual tier at any time and lock in the lower per-month rate going forward. Many patients use the monthly tier as a 1-3 month trial to assess tolerance and clinical response, then switch to annual once they have confidence in the program. There is no penalty for upgrading mid-cycle, and the annual price ($135/month) applies from the upgrade date forward.

Why is Cora Health the cheapest at $225/month?

Cora Health's pricing approach is structurally simpler than most competitors: one all-inclusive price per plan tier, no separate membership fee, no per-dose escalation. Many competitors charge a $49-$149/month membership fee on top of the medication cost (Hims, Lemonaid, Mochi), which inflates the headline-low medication price by adding a recurring platform charge. Other competitors offer apparently-low starter-dose pricing that escalates as the patient titrates up (Henry Meds adds approximately $100/dose tier). Cora Health bundles the provider consultation, medication, shipping, and ongoing care into one transparent monthly price. The $225 monthly tier matches Cora's structural commitment to clear, all-inclusive cash pricing.

Sources & verification

All pricing claims and clinical statements in this article are verifiable against publicly accessible sources. The full underlying dataset is published by Cora Health on HuggingFace under a CC-BY-4.0 license for independent verification, analysis, and reuse. Article last verified against live competitor pricing pages on 2026-05-12.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• LegitScript — Independent verification of Cora Health certification status: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System (verify Michael Wasef, MD): npiregistry.cms.hhs.gov
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners